Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 6096134, 12 pages
https://doi.org/10.1155/2017/6096134
Review Article

Advancements in Developing Strategies for Sterilizing and Functional HIV Cures

1Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Fudan University, Shanghai 200032, China
2Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University, Shanghai 200032, China
3Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA

Correspondence should be addressed to Shibo Jiang; nc.ude.naduf@gnaijobihs and Lu Lu; nc.ude.naduf@lul

Received 22 January 2017; Accepted 4 April 2017; Published 26 April 2017

Academic Editor: Himanshu Garg

Copyright © 2017 Wei Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. G. Deeks, S. R. Lewin, and D. V. Havlir, “The end of AIDS: HIV infection as a chronic disease,” The Lancet, vol. 382, no. 9903, pp. 1525–1533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Stein, M. S. G. Bonsmann, and H. Streeck, “Barriers to HIV cure,” HLA, vol. 88, no. 4, pp. 155–163, 2016. View at Publisher · View at Google Scholar
  3. J. T. Kimata, A. P. Rice, and J. Wang, “Challenges and strategies for the eradication of the HIV reservoir,” Current Opinion in Immunology, vol. 42, pp. 65–70, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. T.-W. Chun, D. Engel, M. M. Berrey, T. Shea, L. Corey, and A. S. Fauci, “Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8869–8873, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. T.-W. Chun, L. Carruth, D. Finzi et al., “Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection,” Nature, vol. 387, no. 6629, pp. 183–188, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Lisziewicz, E. Rosenberg, J. Lieberman et al., “Control of HIV despite the discontinuation of antiretroviral therapy,” New England Journal of Medicine, vol. 340, no. 21, pp. 1683–1684, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. D. H. Barouch and S. G. Deeks, “Immunologic strategies for HIV-1 remission and eradication,” Science, vol. 345, no. 6193, pp. 169–174, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Spragg, H. De Silva Feelixge, and K. R. Jerome, “Cell and gene therapy strategies to eradicate HIV reservoirs,” Current Opinion in HIV and AIDS, vol. 11, no. 4, pp. 442–449, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Kmietowicz, “Early HIV treatment led to “functional cure” in 14 patients, report researchers,” BMJ, vol. 346, Article ID f1759, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. J. F. Okulicz and O. Lambotte, “Epidemiology and clinical characteristics of elite controllers,” Current Opinion in HIV and AIDS, vol. 6, no. 3, pp. 163–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. L. R. Cockerham and H. Hatano, “Elite control of HIV: is this the right model for a functional cure?” Trends in Microbiology, vol. 23, no. 2, pp. 71–75, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Benjamin, B. K. Berges, A. Solis-Leal, O. Igbinedion, C. L. Strong, and M. R. Schiller, “TALEN gene editing takes aim on HIV,” Human Genetics, vol. 135, no. 9, pp. 1059–1070, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Geng, B. Liu, C. Chen et al., “Development of an attenuated Tat protein as a highly-effective agent to specifically activate HIV-1 latency,” Molecular Therapy, vol. 24, no. 9, pp. 1528–1537, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Limsirichai, T. Gaj, and D. V. Schaffer, “CRISPR-mediated activation of latent HIV-1 expression,” Molecular Therapy, vol. 24, no. 3, pp. 499–507, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Wayengera, “Proviral HIV-genome-wide and pol-gene specific Zinc Finger Nucleases: usability for targeted HIV gene therapy,” Theoretical Biology and Medical Modelling, vol. 8, no. 1, article 26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Qu, P. Wang, D. Ding et al., “Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells,” Nucleic Acids Research, vol. 41, no. 16, pp. 7771–7782, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C. L. Strong, H. P. Guerra, K. R. Mathew, N. Roy, L. R. Simpson, and M. R. Schiller, “Damaging the integrated HIV proviral DNA with TALENs,” PLoS ONE, vol. 10, no. 5, Article ID e0125652, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Qu, P. Wang, D. Ding et al., “Zinc finger nuclease: a new approach for excising HIV-1 proviral DNA from infected human T cells,” Molecular Biology Reports, vol. 41, no. 9, pp. 5819–5827, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. H.-K. Liao, Y. Gu, A. Diaz et al., “Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells,” Nature Communications, vol. 6, article 6413, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Kang, W. He, Y. Huang et al., “Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing,” Journal of Assisted Reproduction and Genetics, vol. 33, no. 5, pp. 581–588, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Kaminski, Y. L. Chen, T. Fischer et al., “Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing,” Scientific Reports, vol. 6, Article ID 22555, 2016. View at Google Scholar
  22. G. Hutter, D. Nowak, M. Mossner et al., “Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation,” New England Journal of Medicine, vol. 360, no. 7, pp. 692–698, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. W. Peterson, P. Younan, K. R. Jerome, and H.-P. Kiem, “Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART,” Gene Therapy, vol. 20, no. 7, pp. 695–702, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. C. De Mendoza, P. Barreiro, L. Benitez, and V. Soriano, “Gene therapy for HIV infection,” Expert Opinion on Biological Therapy, vol. 15, no. 3, pp. 319–327, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. E. E. Perez, J. Wang, J. C. Miller et al., “Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases,” Nature Biotechnology, vol. 26, no. 7, pp. 808–816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Tebas, D. Stein, W. W. Tang et al., “Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV,” The New England Journal of Medicine, vol. 370, no. 10, pp. 901–910, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Badia, E. Riveira-Muñoz, B. Clotet, J. A. Esté, and E. Ballana, “Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1,” Journal of Antimicrobial Chemotherapy, vol. 69, no. 7, pp. 1755–1759, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Holt, J. Wang, K. Kim et al., “Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo,” Nature Biotechnology, vol. 28, no. 8, pp. 839–847, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Li, L. Krymskaya, J. Wang et al., “Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases,” Molecular Therapy, vol. 21, no. 6, pp. 1259–1269, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. C. A. Didigu, C. B. Wilen, J. Wang et al., “Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection,” Blood, vol. 123, no. 1, pp. 61–69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Telenti, “Safety concerns about CCR5 as an antiviral target,” Current Opinion in HIV and AIDS, vol. 4, no. 2, pp. 131–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. M. Durand, J. N. Blankson, and R. F. Siliciano, “Developing strategies for HIV-1 eradication,” Trends in Immunology, vol. 33, no. 11, pp. 554–562, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. J. D. Siliciano, J. Kajdas, D. Finzi et al., “Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells,” Nature Medicine, vol. 9, no. 6, pp. 727–728, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. A. L. Remoli, G. Marsili, A. Battistini, and M. Sgarbanti, “The development of immune-modulating compounds to disrupt HIV latency,” Cytokine and Growth Factor Reviews, vol. 23, no. 4-5, pp. 159–172, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Stein, M. Storcksdieck genannt Bonsmann, and H. Streeck, “Barriers to HIV cure,” HLA, vol. 88, no. 4, pp. 155–163, 2016. View at Publisher · View at Google Scholar
  36. H.-T. Shang, J.-W. Ding, S.-Y. Yu, T. Wu, Q.-L. Zhang, and F.-J. Liang, “Progress and challenges in the use of latent HIV-1 reactivating agents,” Acta Pharmacologica Sinica, vol. 36, no. 8, pp. 908–916, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. N. M. Archin, J. J. Eron, S. Palmer et al., “Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells,” AIDS, vol. 22, no. 10, pp. 1131–1135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. N. M. Archin, A. L. Liberty, A. D. Kashuba et al., “Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy,” Nature, vol. 487, no. 7408, pp. 482–485, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. J. H. Elliott, F. Wightman, A. Solomon et al., “Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy,” PLoS Pathogens, vol. 10, no. 11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Filippakopoulos, J. Qi, S. Picaud et al., “Selective inhibition of BET bromodomains,” Nature, vol. 468, no. 7327, pp. 1067–1073, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. N. M. Archin and D. M. Margolis, “Emerging strategies to deplete the HIV reservoir,” Current Opinion in Infectious Diseases, vol. 27, no. 1, pp. 29–35, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Lu, X. Qu, Y. Shen et al., “The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb,” Scientific Reports, vol. 6, Article ID 24100, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Fernandez and S. L. Zeichner, “Cell line-dependent variability in HIV activation employing DNMT inhibitors,” Virology Journal, vol. 7, article 266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Jiang, E. A. Mendes, P. Kaiser et al., “Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling,” AIDS, vol. 28, no. 11, pp. 1555–1566, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Wang, X. Qu, X. Wang et al., “Specific reactivation of latent HIV-1 with designer zinc-finger transcription factors targeting the HIV-1 5′-LTR promoter,” Gene Therapy, vol. 21, no. 5, pp. 490–495, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Wang, P. Wang, Z. Fu et al., “Designed transcription activator-like effector proteins efficiently induced the expression of latent HIV-1 in latently infected cells,” AIDS Research and Human Retroviruses, vol. 31, no. 1, pp. 98–106, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Qu, H. Ying, X. Wang et al., “Histone deacetylase inhibitor MC1293 induces latent HIV-1 reactivation by histone modification in vitro latency cell lines,” Current HIV Research, vol. 11, no. 1, pp. 24–29, 2013. View at Google Scholar · View at Scopus
  48. P. Wang, X. Qu, X. Wang et al., “As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB,” Antiviral Research, vol. 100, no. 3, pp. 688–697, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Zeng, S. Liu, P. Wang et al., “Dilazep synergistically reactivates latent HIV-1 in latently infected cells,” Molecular Biology Reports, vol. 41, no. 11, pp. 7697–7704, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Shan, K. Deng, N. S. Shroff et al., “Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation,” Immunity, vol. 36, no. 3, pp. 491–501, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Joseph, H. Z. Jian, A. Follenzi et al., “Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity,” Journal of Virology, vol. 82, no. 6, pp. 3078–3089, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Deng, M. Pertea, A. Rongvaux et al., “Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations,” Nature, vol. 517, no. 7534, pp. 381–385, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. M. D. Marsden and J. A. Zack, “Double trouble: HIV latency and CTL escape,” Cell Host and Microbe, vol. 17, no. 2, pp. 141–142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Halper-Stromberg, C.-L. Lu, F. Klein et al., “Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice,” Cell, vol. 158, no. 5, pp. 989–999, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Liu, F. Zou, L. Lu et al., “Chimeric antigen receptor T cells guided by the Single-Chain Fv of a broadly neutralizing antibody specifically and effectively eradicate virus reactivated from latency in CD4(+) T lymphocytes isolated from HIV-1-infected individuals receiving suppressive combined antiretroviral therapy,” Journal of Virology, vol. 90, no. 21, pp. 9712–9724, 2016. View at Publisher · View at Google Scholar
  56. W. S. Lee, T. A. Rasmussen, M. Tolstrup et al., “Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption,” Aids Research and Human Retroviruses, vol. 32, supplement 1, p. 405, 2016. View at Google Scholar
  57. T. C. Rodman and F. H. Pruslin, “Identification of a low-affinity subset of protamine-reactive IgM antibodies present in normal, deficient in AIDS, sera: implications for HIV latency,” Clinical Immunology and Immunopathology, vol. 57, no. 3, pp. 430–440, 1990. View at Publisher · View at Google Scholar · View at Scopus
  58. W. S. Lee, M. S. Parsons, S. J. Kent, and M. Lichtfuss, “Can HIV-1-specific ADCC assist the clearance of reactivated latently infected cells?” Frontiers in Immunology, vol. 6, article 265, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. S. N. Byrareddy, J. Arthos, C. Cicala et al., “Sustained virologic control in SIV+ macaques after antiretroviral and alpha(4)beta(7) antibody therapy,” Science, vol. 354, no. 6309, pp. 197–202, 2016. View at Publisher · View at Google Scholar
  60. M. Rolland, P. T. Edlefsen, B. B. Larsen et al., “Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2,” Nature, vol. 490, no. 7420, pp. 417–420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Lu, Y. Zhu, and S. Jiang, “Is α4β7 a hiding target for HIV vaccines?” Science, 2016. View at Google Scholar
  62. S. P. Fuchs, J. M. Martinez-Navio, M. Piatak, J. D. Lifson, G. Gao, and R. C. Desrosiers, “AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity,” PLoS Pathogens, vol. 11, no. 8, Article ID e1005090, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. M. R. Gardner, L. M. Kattenhorn, H. R. Kondur et al., “AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges,” Nature, vol. 519, no. 7541, pp. 87–91, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. U. M. Abdel-Motal, C. Harbison, T. Han et al., “Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer,” Gene Therapy, vol. 21, no. 9, pp. 802–810, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. A. B. Balazs, J. Chen, C. M. Hong, D. S. Rao, L. Yang, and D. Baltimore, “Antibody-based protection against HIV infection by vectored immunoprophylaxis,” Nature, vol. 481, no. 7379, pp. 81–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. J. A. Horwitz, A. Halper-Stromberg, H. Mouquet et al., “HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 41, pp. 16538–16543, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. R. Gautam, Y. Nishimura, A. Pegu et al., “A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges,” Nature, vol. 533, no. 7601, pp. 105–109, 2016. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Caskey, F. Klein, J. C. C. Lorenzi et al., “Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117,” Nature, vol. 522, no. 7557, pp. 487–491, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. J. F. Scheid, J. A. Horwitz, Y. Bar-On et al., “HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption,” Nature, vol. 535, no. 7613, pp. 556–560, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Schoofs, F. Klein, M. Braunschweig et al., “HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1,” Science, vol. 352, no. 6288, pp. 997–1001, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Lu, C. Pan, Y. Li, H. Lu, W. He, and S. Jiang, “A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains,” Retrovirology, vol. 9, article 104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. W. Xu, Q. Wang, F. Yu, L. Lu, and S. Jiang, “Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs,” Journal of Acquired Immune Deficiency Syndromes, vol. 67, no. 2, pp. 1–6, 2014. View at Publisher · View at Google Scholar
  73. W. Chen, Z. Zhu, Y. Feng, and D. S. Dimitrov, “Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 44, pp. 17121–17126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. W. Z. Chen, Y. Feng, P. Prabakaran et al., “Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains,” Journal of Virology, vol. 88, no. 2, pp. 1125–1139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Pantaleo and Y. Levy, “Therapeutic vaccines and immunological intervention in HIV infection,” Current Opinion in HIV and AIDS, vol. 11, no. 6, pp. 576–584, 2016. View at Publisher · View at Google Scholar
  76. G. Mousseau, C. F. Kessing, R. Fromentin, L. Trautmann, N. Chomont, and S. T. Valente, “The tat inhibitor didehydro-cortistatin a prevents HIV-1 reactivation from latency,” mBio, vol. 6, no. 4, Article ID e00465-15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. D. Purcell, J. Jacobson, L. Harty et al., “HIV-specific latency reversing therapies that exploit novel pathways for suboptimal Tat protein expression,” Journal of the International Aids Society, vol. 18, 2015. View at Publisher · View at Google Scholar
  78. D. A. Donahue, B. D. Kuhl, R. D. Sloan, and M. A. Wainberg, “The viral protein tat can inhibit the establishment of HIV-1 latency,” Journal of Virology, vol. 86, no. 6, pp. 3253–3263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. S. K. Song, H. Li, and M. W. Cloyd, “Rates of shutdown of HIV-1 into latency: roles of the LTR and tat/rev/vpu gene region,” Virology, vol. 225, no. 2, pp. 377–386, 1996. View at Publisher · View at Google Scholar · View at Scopus
  80. D. C. Chan, D. Fass, J. M. Berger, and P. S. Kim, “Core structure of gp41 from the HIV envelope glycoprotein,” Cell, vol. 89, no. 2, pp. 263–273, 1997. View at Publisher · View at Google Scholar · View at Scopus
  81. E. Bianchi, J. G. Joyce, M. D. Miller et al., “Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 23, pp. 10655–10660, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. Z. Qi, C. E. Pan, H. Lu et al., “A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice,” Biochemical and Biophysical Research Communications, vol. 398, no. 3, pp. 506–512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Golding, M. Zaitseva, E. De Rosny et al., “Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates,” Journal of Virology, vol. 76, no. 13, pp. 6780–6790, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. Q. Wang, W. Bi, X. Zhu et al., “Nonneutralizing antibodies induced by the HIV-1 gp41 NHR domain gain neutralizing activity in the presence of the HIV fusion inhibitor enfuvirtide: a potential therapeutic vaccine strategy,” Journal of Virology, vol. 89, no. 13, pp. 6960–6964, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Richard, M. Veillette, N. Brassard et al., “CD4 mimetics sensitize HIV-1-infected cells to ADCC,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 20, pp. E2687–E2694, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. W. S. Lee, T. A. Rasmussen, M. Tolstrup et al., “Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption,” Aids Research and Human Retroviruses, vol. 32, article 405, 2016. View at Google Scholar
  87. G. Lehrman, I. B. Hogue, S. Palmer et al., “Depletion of latent HIV-1 infection in vivo: a proof-of-concept study,” Lancet, vol. 366, no. 9485, pp. 549–555, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. K. Imai, K. Yamada, M. Tamura, K. Ochiai, and T. Okamoto, “Reactivation of latent HIV-1 by a wide variety of butyric acid-producing bacteria,” Cellular and Molecular Life Sciences, vol. 69, no. 15, pp. 2583–2592, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Wightman, P. Ellenberg, M. Churchill, and S. R. Lewin, “HDAC inhibitors in HIV,” Immunology and Cell Biology, vol. 90, no. 1, pp. 47–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Matalon, T. A. Rasmussen, and C. A. Dinarello, “Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir,” Molecular Medicine, vol. 17, no. 5-6, pp. 466–472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. T. A. Rasmussen, M. Tolstrup, C. R. Brinkmann et al., “Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial,” The Lancet HIV, vol. 1, no. 1, pp. E13–E21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. S. G. Lin, Y. H. Zhang, H. Ying, and H. Zhu, “HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells,” Current HIV Research, vol. 9, no. 4, pp. 202–208, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Ying, Y. Zhang, S. Lin, Y. Han, and H.-Z. Zhu, “Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines,” International Journal of Molecular Medicine, vol. 26, no. 2, pp. 265–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. H. Ying, Y. H. Zhang, X. Zhou et al., “Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB,” PLoS ONE, vol. 7, no. 11, Article ID e48832, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. F. Wightman, H. K. Lu, A. E. Solomon et al., “Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells,” AIDS, vol. 27, no. 18, pp. 2853–2862, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. O. S. Søgaard, M. E. Graversen, S. Leth et al., “The depsipeptide romidepsin reverses HIV-1 latency in vivo,” PLoS Pathogens, vol. 11, no. 9, Article ID e1005142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Boehm, V. Calvanese, R. D. Dar et al., “BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism,” Cell Cycle, vol. 12, no. 3, pp. 452–462, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. M.-C. Bowman, N. M. Archin, and D. M. Margolis, “Pharmaceutical approaches to eradication of persistent HIV infection,” Expert Reviews in Molecular Medicine, vol. 11, article e6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Vandergeeten, R. Fromentin, S. DaFonseca et al., “Interleukin-7 promotes HIV persistence during antiretroviral therapy,” Blood, vol. 121, no. 21, pp. 4321–4329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. W. Bernhard, K. Barreto, A. Saunders, M. S. Dahabieh, P. Johnson, and I. Sadowski, “The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response,” FEBS Letters, vol. 585, no. 22, pp. 3549–3554, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. J. Friedman, W.-K. Cho, C. K. Chu et al., “Epigenetic silencing of HIV-1 by the histone H3 Lysine 27 methyltransferase enhancer of Zeste 2,” Journal of Virology, vol. 85, no. 17, pp. 9078–9089, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Bouchat, J.-S. Gatot, K. Kabeya et al., “Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients,” AIDS, vol. 26, no. 12, pp. 1473–1482, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. S. K. Choudhary, N. M. Archin, and D. M. Margolis, “Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4+ T cells,” Journal of Infectious Diseases, vol. 197, no. 8, pp. 1162–1170, 2008. View at Publisher · View at Google Scholar · View at Scopus